Axcella flunks long Covid PhII primary goal — but plots a path into PhIII

Kyle LaHucik

Senior Reporter

As Covid-19 cases mount once again and millions of people experience lingering symptoms months after diagnosis, Axcella Therapeutics wants to treat long Covid, but like …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Axcella flunks long Covid PhII primary goal — but plots a path into PhIII

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ax­cel­la flunks long Covid PhII pri­ma­ry goal — but plots a path in­to PhI­II

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Will CRISPR mat­ter?

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Axcella flunks long Covid PhII primary goal — but plots a path into PhIII

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence